Krystal looks to Phase III as stock soars on data for gene therapy

With its lead gene therapy showing efficacy in healing wounds in a rare skin condition, Krystal has seen its market cap multiply sixfold since its 2017 IPO as it now looks

Read the full 314 word article

User Sign In